Age-related hearing impairment 2

Summary

Age-related hearing impairment 2 (MONDO:0013068) is a disease. A subtype of inherited auditory system disease — broader associated-gene and molecular evidence is on the parent page (see Disease family below).

Clinical features

No curated clinical features (Orphanet) for this disease.

Identifiers

Disease identifiers

Field	Value
Canonical name	age-related hearing impairment 2
Mondo ID	MONDO:0013068
MeSH	C567834
OMIM	612976
UMLS	C2751814
MedGen	416639
Is cancer (heuristic)	no

Also known as: age-related hearing impairment 2 · ARHI2

Disease family

Classification path: disease › human disease › disease by body system or component › auditory system disorder › inherited auditory system disease › age-related hearing impairment 2

Related subtypes (11): otosclerosis, Meniere disease, motion sickness, Johanson-Blizzard syndrome, age-related hearing impairment 1, nonsyndromic genetic hearing loss, X-linked deafness, auditory neuropathy, tympanic paraganglioma, benign paroxysmal positional vertigo, vertigo, benign recurrent, 1

Genetics & variants

GWAS landscape

No GWAS associations recorded — common-variant (GWAS) studies don’t cover this disease (typical for Mendelian / rare diseases). See the curated gene cohort and Mendelian overlap below.

Variant details and genetic-evidence tiers

No tiered GWAS variants or ClinVar records for this disease.

Genes & proteins

No associated-gene cohort resolved for this disease. Atlas builds the molecular and therapeutic sections — associated genes, protein families, druggability, pathways, interactions, and drug associations — by aggregating over a disease’s associated genes (resolved via GWAS / GenCC / ClinVar / CIViC), and none resolved here. This is expected for antibody-mediated, autoimmune, or otherwise non-gene-defined conditions; the curated evidence for this disease is its clinical features, GWAS susceptibility, and clinical trials (above).

Function

No pathway enrichment — requires an associated-gene cohort.

Therapeutics

No druggable-target or therapeutic data for this disease’s cohort.

Clinical trials & evidence

Clinical trials

Clinical trials: 0.